Abstract
e16119Background: Benefit of CT beyond standard 1st-line (L1) gemcitabine plus cisplatin (GEMCIS) or oxaliplatin (GEMOX) in aBTC is unclear. Our aim was to identify and validate prognostic factors ...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have